Online ISSN: 3007-0244,
Print ISSN:  2410-4280
POSSIBILITIES OF USING URSODEOXYCHOLIC ACID FOR THE PREVENTION OF ATHEROSCLEROSIS AND LIVER FIBROSIS IN ROUTINE PRACTICE AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFLD/NASH) in the world practice is steadily increasing. NAFLD/NASH can progress to liver cirrhosis and hepatocellular carcinoma. However, most patients with NAFLD/NASH die due to cardiovascular events. It should be noted that the prevalence of NAFLD is increasing parallel to the rising cases of type 2 diabetes (T2D) and obesity. Despite the growing number of patients, therapeutic approaches remain limited. This article presents the results of using ursodeoxycholic acid (UDCA) in NAFLD/NASH. Previously, according to various sources, it was found that bile acids, which include UDCA, are the main integrators of fatty acid and triglyceride metabolism in the liver. The results of our study showed that the use of UDCA in NAFLD leads to a decrease in the activity of inflammatory processes in the liver, its steatosis, and also improves lipid metabolism and has potential anti-atherogenic properties.
Number of Views: 177

Key words:

Category of articles: Original articles

Bibliography link

Raisova A.M., Nersesov A.V., Kaibullaeva D.A., Konysbekova A.U., Ismagulova M.A., Madenova S.S., Nefedova M.A., Tatieva M.A., Tashenova L.K., Kaliaskarova K.S., Konysbekova A.A., Alieva Sh.B., Dzhakupova G.M., Lipkina E.I., Nadinskaya M.Yu. Possibilities of using ursodeoxycholic acid for the prevention of atherosclerosis and liver fibrosis in routine practice among patients with non-alcoholic fatty liver disease // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 4, pp. 33-41. doi 10.34689/SH.2023.25.4.004

Авторизируйтесь для отправки комментариев